QuidelOrtho Corp Director Purchases 10k Shares as CFO Retires

Core Insights - Matthew Strobeck, a Board Director at QuidelOrtho Corp., purchased 10,000 common shares for approximately $240,000, indicating confidence in the company's future [1][2]. Transaction Summary - The transaction involved 10,000 shares traded at a value of $239,586, with a reported price of $23.96 per share [2]. - Post-transaction, Strobeck holds 27,775 shares directly, valued at approximately $655,000 based on the market close price of $23.58 on February 13, 2026 [2][4]. - This acquisition represents 13.78% of Strobeck's total reported holdings and 56.26% of his direct stake [4]. Company Overview - QuidelOrtho Corporation is a global diagnostics testing solutions company with a diverse portfolio that includes laboratory, transfusion medicine, point-of-care, and molecular testing platforms [6]. - The company serves a wide range of clients, including healthcare providers, laboratories, blood banks, donor centers, and retail channels globally [6]. Financial Performance - QuidelOrtho reported a revenue of $2.73 billion for the trailing twelve months (TTM) but experienced a net loss of $1.13 billion [5]. - The company has seen a 1.89% year-over-year decline in revenue for Q4 FY 2025, marking the third consecutive year of declining annual revenue [8]. - QuidelOrtho's stock has declined approximately 44.37% over the past year, with a 23% drop so far in 2026 [5][7]. Executive Changes - The company is undergoing significant structural changes, including the retirement of CFO Joseph M. Busky, which necessitates finding a replacement by June [7]. - This follows a period of instability marked by the firing of the previous President and CEO and substantial workforce layoffs [7].